187 related articles for article (PubMed ID: 21905981)
1. A decision support model for cost-effectiveness of radical prostatectomy in localized prostate cancer.
Lyth J; Andersson SO; Andrén O; Johansson JE; Carlsson P; Shahsavar N
Scand J Urol Nephrol; 2012 Feb; 46(1):19-25. PubMed ID: 21905981
[TBL] [Abstract][Full Text] [Related]
2. Managing localized prostate cancer by radical prostatectomy or watchful waiting: Cost analysis of a randomized trial (SPCG-4).
Andersson SO; Andrén O; Lyth J; Stark JR; Henriksson M; Adami HO; Carlsson P; Johansson JE
Scand J Urol Nephrol; 2011 Apr; 45(3):177-83. PubMed ID: 21265595
[TBL] [Abstract][Full Text] [Related]
3. A short-term cost-effectiveness study comparing robot-assisted laparoscopic and open retropubic radical prostatectomy.
Hohwü L; Borre M; Ehlers L; Venborg Pedersen K
J Med Econ; 2011; 14(4):403-9. PubMed ID: 21604962
[TBL] [Abstract][Full Text] [Related]
4. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
5. Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.
Johansson E; Steineck G; Holmberg L; Johansson JE; Nyberg T; Ruutu M; Bill-Axelson A;
Lancet Oncol; 2011 Sep; 12(9):891-9. PubMed ID: 21821474
[TBL] [Abstract][Full Text] [Related]
6. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
[TBL] [Abstract][Full Text] [Related]
7. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
[TBL] [Abstract][Full Text] [Related]
8. Time, symptom burden, androgen deprivation, and self-assessed quality of life after radical prostatectomy or watchful waiting: the Randomized Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) clinical trial.
Johansson E; Bill-Axelson A; Holmberg L; Onelöv E; Johansson JE; Steineck G;
Eur Urol; 2009 Feb; 55(2):422-30. PubMed ID: 18783877
[TBL] [Abstract][Full Text] [Related]
9. Management of localised prostate cancer: watchful waiting, surgery or radiation therapy, depending on the natural course, which is often relatively slow.
Prescrire Int; 2012 Oct; 21(131):242-8. PubMed ID: 23185849
[TBL] [Abstract][Full Text] [Related]
10. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
11. A framework to evaluate the cost-effectiveness of the NADiA ProsVue slope to guide adjuvant radiotherapy among men with high-risk characteristics following prostatectomy for prostate cancer.
Reed SD; Stewart SB; Scales CD; Moul JW
Value Health; 2014 Jul; 17(5):545-54. PubMed ID: 25128047
[TBL] [Abstract][Full Text] [Related]
12. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
13. Unusually large numbers needed to treat for radical prostatectomy in prostate cancer patients with PSA velocity ≤2 ng/ml/year.
Scheerer J; Kahabka P; Altwein JE; Weißbach L
Urol Int; 2012; 89(2):155-61. PubMed ID: 22814092
[TBL] [Abstract][Full Text] [Related]
14. Percentage of positive biopsy cores, preoperative prostate-specific antigen (PSA) level, pT and Gleason score as predictors of PSA recurrence after radical prostatectomy: a multi-institutional outcome study in Japan.
Yokomizo A; Murai M; Baba S; Ogawa O; Tsukamoto T; Niwakawa M; Tobisu K; Kinukawa N; Naito S
BJU Int; 2006 Sep; 98(3):549-53. PubMed ID: 16925752
[TBL] [Abstract][Full Text] [Related]
15. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
[TBL] [Abstract][Full Text] [Related]
16. Biochemical outcome after radical prostatectomy or external beam radiation therapy for patients with clinically localized prostate carcinoma in the prostate specific antigen era.
D'Amico AV; Whittington R; Malkowicz SB; Cote K; Loffredo M; Schultz D; Chen MH; Tomaszewski JE; Renshaw AA; Wein A; Richie JP
Cancer; 2002 Jul; 95(2):281-6. PubMed ID: 12124827
[TBL] [Abstract][Full Text] [Related]
17. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
18. Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy.
Zhou P; Chen MH; McLeod D; Carroll PR; Moul JW; D'Amico AV
J Clin Oncol; 2005 Oct; 23(28):6992-8. PubMed ID: 16192586
[TBL] [Abstract][Full Text] [Related]
19. Future benefits and cost-effectiveness of prostate carcinoma screening. American Cancer Society.
Littrup PJ
Cancer; 1997 Nov; 80(9):1864-70. PubMed ID: 9351561
[TBL] [Abstract][Full Text] [Related]
20. Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study.
Steuber T; Budäus L; Walz J; Zorn KC; Schlomm T; Chun F; Ahyai S; Fisch M; Sauter G; Huland H; Graefen M; Haese A
BJU Int; 2011 Jun; 107(11):1755-61. PubMed ID: 20942833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
